Acceleron Pharma and Collaborators Present Data on Potential Biomarkers for Metastatic Breast Cancer and Head and Neck Cancer at the "2012 Markers in Cancer" Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, and its collaborators are presenting data at the 2012 Markers in Cancer Conference in Hollywood, Fla., a joint meeting sponsored by ASCO, EORTC, and the NCI, that illustrate possible new biomarkers for use in metastatic breast cancer and in squamous cell carcinoma of the head and neck. The two poster presentations describe the potential role of activin A as an adverse biomarker for patients with metastatic breast cancer and of BMP9 as a biomarker for the identification and selection of patients with head and neck cancer. Acceleron is focused on developing novel medicines that regulate members of TGF-ß superfamily of proteins, which include BMP9 and activin A. These proteins play fundamental roles in regulating the growth and differentiation of various cell types and are involved in diseases such as cancer.